Accuray Ranked 274th Fastest Growing Company in North America on Deloitte's 2011 Technology Fast 500™

Exceptional 319 Percent Revenue Growth from 2006-2010 to be Enhanced by TomoTherapy Acquisition

News provided by

Oct 19, 2011, 10:18 ET

SUNNYVALE, Calif., Oct. 19, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that it ranked 274th on Deloitte's Technology Fast 500™ ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2006 to 2010; during this period, Accuray grew 319 percent.

Accuray manufactures two of the radiation oncology industry's leading-edge technologies: the CyberKnife® Robotic Radiosurgery System, a premier radiosurgery/stereotactic body radiotherapy (SRS/SBRT) solution, and the TomoTherapy® Radiation Therapy System, an innovative daily image-guided intensity modulated radiation therapy (IMRT) platform. Together, the two systems allow Accuray to deliver advanced, personalized treatment solutions for almost every cancer patient.

"Accuray is proud to be honored as one of the fastest growing companies in North America," said Euan Thomson, Ph. D., chief executive officer, Accuray Incorporated. "This award acknowledges the growth of our core business prior to our acquisition of TomoTherapy in June of 2011. We expect the powerful combination of the CyberKnife and TomoTherapy Systems to promote supplementary growth for the company in the future."

"Accuray, like all 2011 Technology Fast 500™ companies, has excelled in fostering innovation and channeling it into spectacular growth -- against the backdrop of one of the most challenging economies in history," said Eric Openshaw, vice chairman and U.S. technology, media and telecommunications leader, Deloitte LLP. "Deloitte recognizes Accuray for its remarkable accomplishment."

"We are pleased to honor Accuray as a 2011 Technology Fast 500 company," said Mark Jensen, managing partner, technology and venture capital services, Deloitte & Touche LLP. "As one of the fastest growing tech companies in North America, Accuray has demonstrated excellence in technological innovation, entrepreneurship and rapid growth."

Accuray has been ranked in Deloitte's Technology Fast 500 every year since 2008, and in 2010, was ranked #113 on the Technology Fast 500™ list.

Overall, 2011 Technology Fast 500™ companies achieved revenue growth ranging from 134 percent to 70,211 percent from 2006 to 2010, with an average growth of 1,736 percent.

About Deloitte's 2011 Technology Fast 500™

Technology Fast 500, which was conducted by Deloitte & Touche LLP, a subsidiary of Deloitte LLP, provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies – both public and private – in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2006 to 2010.

In order to be eligible the Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company's operating revenues. Companies must have base-year operating revenues of at least $50,000 USD or CD, and current-year operating revenues of at least $5 million USD or CD. Additionally, companies must be in business for a minimum of five years, and be headquartered within North America.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy and adaptive radiation therapy. To date, more than 200,000 patients worldwide have been treated using the Company's technologies and more than 582 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.

Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to products, technology and growth are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: products, clinical applications, and market acceptance of products and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for our 2011 fiscal year filed on September 19, 2011 and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

SOURCE Accuray Incorporated